The University of Calgary Department of Oncology and the Arnie Charbonneau Cancer Institute awarded $18,750 to Dr. Bathe and colleagues in endocrine surgery and pathology. The seed grant will be used to test Thyroid GuidePx™ in formalin fixed paraffin embedded…
Qualisure Diagnostics Inc. and Protean BioDiagnostics Inc. together will perform the technical validation essential to launch Thyroid GuidePx™ as a Laboratory Developed Test in the United States. Protean BioDiagnostics is a CAP/CLIA certified lab focused on Precision Oncology. Protean’s commitment…
Qualisure Diagnostics Inc. and OncoHelix Inc. will collaborate to prepare Thyroid GuidePx™ for introduction to the clinic. OncoHelix’s expertise in next generation sequencing (NGS) and Precision Oncology will be leveraged to perform the validation necessary to make this test available…
Qualisure was awarded a $295,000 Alberta Innovates AICE-Validate grant to support further development of Thyroid GuidePx™, the next phase of the Molecular deCodeR build, and market access work. The AICE-Validate program is an opportunity for Alberta’s health-tech innovators to accelerate…
Qualisure Diagnostics Inc. has been assigned 11 pieces of intellectual property, including the HighLifeR machine learning algorithm, the Molecular deCodeR software, and a number of prognostic biomarkers that will guide treatments of cancer. Innovate Calgary, the innovation transfer and business…
Qualisure Diagnostics Inc. researcher receives the Dr. Selwyn Taylor Award for best scientific presentation at the 48th World Congress of Surgery in Krakow, Poland Dr. Steven Craig, one of our key opinion leaders and co-creator of our prognostic test for…
Qualisure Diagnostics wins two international pitch competitions at INVENTURE$ 2019 Inventures is Alberta Innovates’ signature innovation event in Calgary. Over three days, Inventures 2019 brought together venture capitalists, angel investors, startups, entrepreneurs, service providers and thought leaders. The multi-stream and…